EGFR and non-small cell lung carcinoma: In the North East Japan (NEJ) 002 and West Japan Thoracic Oncology Group 3405 trials of gefitinib versus chemotherapy in patients with EGFR mutation-positive NSCLC, gefitinib extended the PFS (median PFS, 10.8 months for gefitinib vs. 5.4 months for chemotherapy; hazard ratio (HR), 0.30; p < 0.001 and median PFS, 9.2 months for gefitinib vs. 6.3 months for chemotherapy; HR, 0.48; p < 0.0001, respectively) [14,15].